If you need more lookups,
subscriptions start at $34 USD/month.
Adam Craig Location
United Kingdom
Adam Craig Work
2025 -now Strategic Advisor, Hematology @
2025 -now Executive Chairman @
2025 -now Member Board of Directors @
2025 -2025 Member Board of Directors @
2024 -2025 Member Board of Directors @
2024 -2025 Interim President and Chief Executive Officer @
2024 -2026 Strategic Advisor @
2023 -now Strategic Advisor @
2017 -2023 President and Chief Executive Officer @ CTI BioPharma Corp.
2012 -2015 EVP, Development and Chief Medical Officer @
2016 -2016 Interim Chief Medical Officer @ Immune Design
2007 -2011 Chief Medical Officer, Senior Vice President @ ChemGenex Pharmaceuticals, Inc. (a wholly owned subsidiary of Teva Pharmaceutica
2015 -2017 President @ Medarc Consulting LLC
Adam Craig Education
Molecular Medicine Unit, University of Leeds
PhD (Molecular Pathology of Acute Leukemia)
Charing Cross and Westminster Medical School, University of London
MB BS, BSc (Hons.)
Adam Craig Skills
Life Sciences
Oncology
Clinical Development
Drug Development
Pharmaceutical Industry
Infectious Diseases
Lifesciences
Clinical Trials
Biopharmaceuticals
Biotechnology
Drug Discovery
CRO
Commercialization
Regulatory Affairs
Management
Clinical Research
Business Development
Healthcare
Customer Service
Process Improvement
Sales
Adam Craig Summary
Adam Craig, based in United Kingdom, is currently a Strategic Advisor, Hematology at Syntara. Adam Craig brings experience from previous roles at X4 Pharmaceuticals, eGenesis, Inc., Stratus Therapeutics and Garuda Therapeutics. Adam Craig holds a PhD in Molecular Pathology of Acute Leukemia @ Molecular Medicine Unit, University of Leeds. With a robust skill set that includes Life Sciences, Oncology, Clinical Development, Drug Development, Pharmaceutical Industry and more. Adam Craig has 5 emails and 6 mobile phone numbers on RocketReach.
Looking for a different Adam Craig?
Find contact details for 700 million professionals.